查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年全球數位生物標記市場預測：按類型、實踐、治療領域、資料收集工具、用途、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1372022

到 2030 年全球數位生物標記市場預測：按類型、實踐、治療領域、資料收集工具、用途、最終用戶和地區進行的全球分析

Digital Biomarkers Market Forecasts to 2030 - Global Analysis By Type (Sensors, Mobile Based Applications, Wearable and Other Types), Clinical Practice, Therapeutic Area, Data Collection Tool, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球數位生物標記市場規模將達到 35 億美元，預計到 2030 年將達到 127 億美元，預測期內年複合成長率為 20.3%。

數位生物標記是從數位平台和設備收集的公正的、可量化的檢測，可提供對人的行為和健康的認知。這些生物標記物可以來自各個地方，包括穿戴式科技、智慧型手機應用程式、感測器和其他數位健康科技。數位生物標記包括各種資料，包括生理、行為和檢測資料。

據帕金森氏症基金會稱，到2022年，美國每年將有近9萬人被診斷出患有帕金森氏症。

醫療保健數位化的進展

醫療領域數位化的進步正在改變醫學研究、診斷和治療的一切。數位生物標記是消費者使用數位健康技術直接收集的有關其健康和疾病管理的資料，以揭示、影響或預測健康領域。它屬於。此外，數位生物標記的使用有可能有益於患者的健康，因為它們對於診斷和預後預測變得至關重要。

資料安全問題

資料安全問題也是阻礙全球數位生物標記市場的要素之一。該領域面臨的最大問題之一是安全和隱私風險，因為資料的性質使其容易受到駭客攻擊和資料竊取。然而，數位治療產品和服務容易受到外部干擾、訊號損傷和傳輸損傷。結果，重要的患者資料可能會遺失。因此，數位生物標記的全球市場開拓預計將受到此類要素的阻礙。

穿戴式裝置的使用增加

隨著人們對自己的健康、健身和整體福祉的意識日益增強，尤其是在新冠肺炎 (COVID-19) 疫情之後，穿戴式裝置的使用在全球範圍內迅速增加。穿戴式健康監測技術有助於追蹤佩戴者的健康資訊。此外，隨著市場領導者推出先進、易於使用的監測生命徵象的穿戴式設備，對數位生物標記的需求也在成長。預計這一趨勢將在預測期內持續下去，為市場擴張創造機會。

高資本支出

生物標記的發現、開發和檢驗需要大量的收益支出。然而，進行臨床試驗並遵守嚴格的法規標準需要大量資金，這對世界創新能力和小型企業產生負面影響。這些因素阻礙了市場的成長。

COVID-19 的影響

專家們正在尋求數位指標，以促進對受大流行影響的人們進行遠端篩檢和診斷。此外，許多醫療技術公司正在提供數位生物標記技術來幫助阻止 COVID-19 的爆發。由於這些投資，預計市場將在預測期內擴大。由於 COVID-19 疫情造成的嚴重困難，政府機構表示有興趣開發基於數位生物標記的藥物。

預計神經系統疾病領域在預測期內將是最大的。

預計神經系統疾病領域在預測期內將是最大的。用於監測、鑒定和管理各種神經系統疾病的數位生物標記的開拓和應用是全球數位生物標記市場中神經系統疾病領域的主要焦點。此外，這些生物標記也用於監測阿茲海默症、帕金森氏症、癲癇和多發性硬化症等疾病的發病和症狀。透過持續監測患者的生理和行為資料，醫療保健提供者可以即時了解神經系統疾病，從而實現早期療育和個人化治療策略。

預計疼痛管理領域在預測期內複合年複合成長率最高

預計疼痛管理領域在預測期內年複合成長率最高。利用數位健康技術來監測、評估和治療與慢性疼痛相關的疾病是這部分市場的焦點。此外，透過穿戴式科技、行動應用程式和遠端監控系統收集的數位生物標記可以提供有關疼痛程度、持續時間和患者對各種治療的反應的公正且連續的資訊。這些生物標記提供了更專業、更精確的疼痛管理方法，幫助患者和醫療保健專業人員更好地了解和治療慢性疼痛。

佔比最高的地區

由於人口眾多且多樣化、醫療保健系統不斷擴大以及智慧型手機和穿戴式裝置的普及不斷提高，亞太地區預計將在預測期內佔據最大佔有率。此外，該地區為採用數位生物標記物提供了重要機會。糖尿病、心臟病和癌症等慢性病在亞洲和太平洋地區很常見。

複合年複合成長率最高的地區

據估計，亞太地區的年複合成長率最高。該地區在醫療保健基礎設施和技術方面進行了大量投資，促進了數位醫療解決方案的發展。此外，遠端醫療、穿戴式科技以及支持數位健康配合措施的政府和私人公司進一步推動了對數位生物標記物的需求。

提供免費客製化

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球數位生物標記市場：按類型

  • 感應器
  • 基於行動的應用程式
  • 穿戴式的
  • 其他類型

第6章 全球數位生物標記市場：依醫療實踐分類

  • 用於預測和預後的數位生物標記物
  • 數位生物標記監測
  • 診斷數位生物標記
  • 其他醫療活動

第7章 全球數位生物標記市場：按治療領域

  • 神經系統疾病
  • 睡眠/運動疾病
  • 精神障礙
  • 呼吸系統疾病
  • 心血管疾病/代謝紊亂
  • 肌肉骨骼疾病
  • 其他治療領域

第8章 全球數位生物標記市場：依資料收集工具分類

  • 資料整合
  • 基於桌面的軟體
  • 其他資料收集工具

第9章 全球數位生物標記市場：依用途

  • 情緒/行為
  • 疼痛管理
  • 神經退化性疾病
  • 其他用途

第10章 全球數位生物標記市場：依最終用戶分類

  • 糖尿病
  • 醫療服務提供方
  • 生物製藥公司
  • 其他最終用戶

第11章全球數位生物標記市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • Abbott
  • ActiGraph LLC
  • Adherium Limited
  • AliveCor, Inc
  • Alphabet, Inc
  • Altoida Inc.
  • Amgen Inc.
  • Aural Analytic
  • Bayer AG
  • Biogen Inc.
  • Empatica Inc.
  • Evidation Health, Inc
  • Feel Therapeutics
  • Fitbit, Inc
  • GlaxoSmithKline Plc
  • Happify Health
  • Kinsa Inc.
  • Koneksa
  • Medopad Ltd
  • Mindstrong Health
  • Neurotrack Technologies, Inc.
  • Novartis International AG
  • Pfizer Inc
  • Sanofi SA
  • Sonde Health, Inc.
  • Verily Life Sciences
  • Vivo Sense
Product Code: SMRC24078

According to Stratistics MRC, the Global Digital Biomarkers Market is accounted for $3.5 billion in 2023 and is expected to reach $12.7 billion by 2030 growing at a CAGR of 20.3% during the forecast period. Digital biomarkers are unbiased, quantifiable measurements gathered from digital platforms or devices that offer perceptions of a person's behavior or health. These biomarkers come from many different places, including wearable technology, smartphone apps, sensors, and other digital health technologies. A wide range of physiological, behavioral, or biometric data can be included in digital biomarkers.

According to Parkinson's Foundation, in 2022, nearly 90,000 people were reported to have been diagnosed with Parkinson's disease in the U.S. each year.

Market Dynamics:

Driver:

Increasing the digitization of healthcare

Medical research, diagnostics, and therapies have all been transformed by rising levels of digitization in the healthcare sector. Digital biomarkers are data that consumers directly collect about their own health or illness management using digital health technology in order to clarify, affect, and/or anticipate results in the area of their health. Additionally, the use of digital biomarkers can help patients' health because they are becoming more and more essential in diagnoses and prognostics.

Restraint:

Concerns about data security

Data security issues are an additional factor that's hampering the global market for digital biomarkers. One of the biggest issues facing the sector is security and privacy hazards because of the nature of data and its susceptibility to hacker assaults and data theft. However, digital therapeutic products and services are susceptible to external interference, signal faults, and transmission failures. Critical patient data could be lost as a result of this. The development of the global market for digital biomarkers is then anticipated to be hampered by this.

Opportunity:

Increased use of wearables

Wearable device usage is rising rapidly all across the world in conjunction with the rising public awareness of health, fitness, and overall well-being, particularly in the wake of COVID-19. Wearable health monitoring technology aids in tracking the wearer's health information. Additionally, the demand for digital biomarkers has also expanded as a result of the market leaders' introduction of user-friendly, cutting-edge wearables to monitor vital signs. Over the projection period, this tendency is anticipated to continue, creating opportunity for the market expansion.

Threat:

High capital expenditures

The discovery, development, and/or validation of biomarkers require a significant revenue expenditure. However, a significant amount of capital is needed to conduct clinical trials and adhere to strict regulatory standards, which has a negative impact on innovation and the capabilities of small businesses globally. These elements are hindering market growth.

COVID-19 Impact:

Digital indicators that would make it easier to remotely screen and diagnose COVID-19 people impacted by the current pandemic situation are being sought after by medical specialists. Additionally, a number of health technology companies have contributed their digital biomarker technologies to help stop the COVID-19 outbreak. As a result of this investment, the market is expected to expand over the course of the projected period. Due to the severe hardship caused by the COVID-19 outbreak, governmental entities have indicated interest in developing digital biomarker-based medications.

The neurological disorders segment is expected to be the largest during the forecast period

Neurological Disorders segment is expected to be the largest during the forecast period. The development and application of digital biomarkers to monitor, identify, and manage a variety of neurological illnesses is the primary emphasis of the neurological disorders area of the global market for digital biomarkers. Additionally, these biomarkers are used in this section to monitor the development and symptoms of diseases like Alzheimer's, Parkinson's, epilepsy, multiple sclerosis, and more. Healthcare providers can acquire real-time insights into neurological illnesses by continually monitoring patients' physiological and behavioral data, enabling early intervention and individualized treatment strategies.

The pain management segment is expected to have the highest CAGR during the forecast period

Pain Management segment is expected to have the highest CAGR during the forecast period. Utilizing digital health technologies to monitor, evaluate, and treat diseases associated with chronic pain is the focus of this section of the market. Additionally, digital biomarkers, which are gathered through wearable technology, mobile applications, and remote monitoring systems, offer unbiased and ongoing information on pain level, duration, and patient response to various therapies. These biomarkers provide a more specialized and accurate approach to pain management, assisting patients and healthcare professionals in better comprehending and treating chronic pain.

Region with largest share:

Due to its sizable and diverse population, expanding healthcare system, and rising smartphone and wearable device penetration, the Asia-Pacific region is expected to hold the largest share over the forecast period. Moreover, this region offers significant opportunities for the adoption of digital biomarkers. Chronic diseases like diabetes, heart disease, and cancer are becoming more prevalent in the Asia-Pacific area.

Region with highest CAGR:

Asia Pacific region is estimated to witness highest CAGR. The region's numerous healthcare infrastructure and technology investments are fostering the development of digital health solutions. Furthermore, the demand for digital biomarkers is being further increased by governments and private businesses that are supporting telemedicine, wearable technologies, and digital health initiatives.

Key players in the market:

Some of the key players in Digital Biomarkers market include: Orthofix Abbott, ActiGraph LLC, Adherium Limited, AliveCor, Inc, Alphabet, Inc, Altoida Inc., Amgen Inc., Aural Analytic, Bayer AG, Biogen Inc., Empatica Inc., Evidation Health, Inc, Feel Therapeutics , Fitbit, Inc, GlaxoSmithKline Plc, Happify Health, Kinsa Inc., Koneksa , Medopad Ltd, Mindstrong Health, Neurotrack Technologies, Inc., Novartis International AG, Pfizer Inc, Sanofi S.A, Sonde Health, Inc., Verily Life Sciences and Vivo Sense.

Key Developments:

In January 2023, Koneksa announced the launch of a clinical study comparing the treatment effect between at-home mobile Spirometry using digital biomarkers and in-clinic Spirometry in patients with moderate asthma on long-acting beta-agonist (LABA) treatment.

In January 2023, Aculys Pharma, Inc. and Four H, Inc. announced the research collaboration using wearable devices to help individuals with narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome (OSAS).

Types Covered:

  • Sensors
  • Mobile Based Applications
  • Wearable
  • Other Types

Clinical Practices Covered:

  • Predictive and Prognostic Digital Biomarkers
  • Monitoring Digital Biomarkers
  • Diagnostic Digital Biomarkers
  • Other Clinical Practices

Therapeutic Areas Covered:

  • Neurological Disorders
  • Sleep & Movement Disease
  • Psychiatric Disorders
  • Respiratory Disorders
  • Cardiovascular and Metabolic Disorders
  • Musculoskeletal Disorders
  • Other Therapeutic Areas

Data Collection Tools Covered:

  • Data Integration
  • Desktop Based Software
  • Other Data Collection Tools

Applications Covered:

  • Mood and Behavior
  • Pain Management
  • Neurodegenerative Disorders
  • Other Applications

End Users Covered:

  • Diabetes
  • Healthcare Providers
  • Biopharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Biomarkers Market, By Type

  • 5.1 Introduction
  • 5.2 Sensors
  • 5.3 Mobile Based Applications
  • 5.4 Wearable
  • 5.5 Other Types

6 Global Digital Biomarkers Market, By Clinical Practice

  • 6.1 Introduction
  • 6.2 Predictive and Prognostic Digital Biomarkers
  • 6.3 Monitoring Digital Biomarkers
  • 6.4 Diagnostic Digital Biomarkers
  • 6.5 Other Clinical Practices

7 Global Digital Biomarkers Market, By Therapeutic Area

  • 7.1 Introduction
  • 7.2 Neurological Disorders
  • 7.3 Sleep & Movement Disease
  • 7.4 Psychiatric Disorders
  • 7.5 Respiratory Disorders
  • 7.6 Cardiovascular and Metabolic Disorders
  • 7.7 Musculoskeletal Disorders
  • 7.8 Other Therapeutic Areas

8 Global Digital Biomarkers Market, By Data Collection Tool

  • 8.1 Introduction
  • 8.2 Data Integration
  • 8.3 Desktop Based Software
  • 8.4 Other Data Collection Tools

9 Global Digital Biomarkers Market, By Application

  • 9.1 Introduction
  • 9.2 Mood and Behavior
  • 9.3 Pain Management
  • 9.4 Neurodegenerative Disorders
  • 9.5 Other Applications

10 Global Digital Biomarkers Market, By End User

  • 10.1 Introduction
  • 10.2 Diabetes
  • 10.3 Healthcare Providers
  • 10.4 Biopharmaceutical Companies
  • 10.5 Other End Users

11 Global Digital Biomarkers Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott
  • 13.2 ActiGraph LLC
  • 13.3 Adherium Limited
  • 13.4 AliveCor, Inc
  • 13.5 Alphabet, Inc
  • 13.6 Altoida Inc.
  • 13.7 Amgen Inc.
  • 13.8 Aural Analytic
  • 13.9 Bayer AG
  • 13.10 Biogen Inc.
  • 13.11 Empatica Inc.
  • 13.12 Evidation Health, Inc
  • 13.13 Feel Therapeutics
  • 13.14 Fitbit, Inc
  • 13.15 GlaxoSmithKline Plc
  • 13.16 Happify Health
  • 13.17 Kinsa Inc.
  • 13.18 Koneksa
  • 13.19 Medopad Ltd
  • 13.20 Mindstrong Health
  • 13.21 Neurotrack Technologies, Inc.
  • 13.22 Novartis International AG
  • 13.23 Pfizer Inc
  • 13.24 Sanofi S.A
  • 13.25 Sonde Health, Inc.
  • 13.26 Verily Life Sciences
  • 13.27 Vivo Sense

List of Tables

  • Table 1 Global Digital Biomarkers Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Digital Biomarkers Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Digital Biomarkers Market Outlook, By Sensors (2021-2030) ($MN)
  • Table 4 Global Digital Biomarkers Market Outlook, By Mobile Based Applications (2021-2030) ($MN)
  • Table 5 Global Digital Biomarkers Market Outlook, By Wearable (2021-2030) ($MN)
  • Table 6 Global Digital Biomarkers Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Digital Biomarkers Market Outlook, By Clinical Practice (2021-2030) ($MN)
  • Table 8 Global Digital Biomarkers Market Outlook, By Predictive and Prognostic Digital Biomarkers (2021-2030) ($MN)
  • Table 9 Global Digital Biomarkers Market Outlook, By Monitoring Digital Biomarkers (2021-2030) ($MN)
  • Table 10 Global Digital Biomarkers Market Outlook, By Diagnostic Digital Biomarkers (2021-2030) ($MN)
  • Table 11 Global Digital Biomarkers Market Outlook, By Other Clinical Practices (2021-2030) ($MN)
  • Table 12 Global Digital Biomarkers Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 13 Global Digital Biomarkers Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 14 Global Digital Biomarkers Market Outlook, By Sleep & Movement Disease (2021-2030) ($MN)
  • Table 15 Global Digital Biomarkers Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 16 Global Digital Biomarkers Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
  • Table 17 Global Digital Biomarkers Market Outlook, By Cardiovascular and Metabolic Disorders (2021-2030) ($MN)
  • Table 18 Global Digital Biomarkers Market Outlook, By Musculoskeletal Disorders (2021-2030) ($MN)
  • Table 19 Global Digital Biomarkers Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 20 Global Digital Biomarkers Market Outlook, By Data Collection Tool (2021-2030) ($MN)
  • Table 21 Global Digital Biomarkers Market Outlook, By Data Integration (2021-2030) ($MN)
  • Table 22 Global Digital Biomarkers Market Outlook, By Desktop Based Software (2021-2030) ($MN)
  • Table 23 Global Digital Biomarkers Market Outlook, By Other Data Collection Tools (2021-2030) ($MN)
  • Table 24 Global Digital Biomarkers Market Outlook, By Application (2021-2030) ($MN)
  • Table 25 Global Digital Biomarkers Market Outlook, By Mood and Behavior (2021-2030) ($MN)
  • Table 26 Global Digital Biomarkers Market Outlook, By Pain Management (2021-2030) ($MN)
  • Table 27 Global Digital Biomarkers Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
  • Table 28 Global Digital Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Global Digital Biomarkers Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Digital Biomarkers Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 31 Global Digital Biomarkers Market Outlook, By Healthcare Providers (2021-2030) ($MN)
  • Table 32 Global Digital Biomarkers Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 33 Global Digital Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.